KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Equity Average (2018 - 2025)

Historic Equity Average for Bionano Genomics (BNGO) over the last 8 years, with Q3 2025 value amounting to $47.6 million.

  • Bionano Genomics' Equity Average fell 2633.61% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year decrease of 2633.61%. This contributed to the annual value of $65.8 million for FY2024, which is 6193.6% down from last year.
  • According to the latest figures from Q3 2025, Bionano Genomics' Equity Average is $47.6 million, which was down 2633.61% from $46.8 million recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Equity Average ranged from a high of $354.3 million in Q2 2021 and a low of $41.8 million during Q1 2025
  • For the 5-year period, Bionano Genomics' Equity Average averaged around $187.3 million, with its median value being $198.9 million (2021).
  • Per our database at Business Quant, Bionano Genomics' Equity Average surged by 6647943.41% in 2021 and then tumbled by 6344.92% in 2024.
  • Quarter analysis of 5 years shows Bionano Genomics' Equity Average stood at $339.3 million in 2021, then dropped by 21.74% to $265.6 million in 2022, then crashed by 59.49% to $107.6 million in 2023, then plummeted by 60.85% to $42.1 million in 2024, then rose by 12.98% to $47.6 million in 2025.
  • Its Equity Average was $47.6 million in Q3 2025, compared to $46.8 million in Q2 2025 and $41.8 million in Q1 2025.